Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TB-005
- Development stage
- Preclinical
- Lead developer
- ThinkingBiomed
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
TB-005 is an experimental, universal "off-the-shelf" immune cell therapy being developed by ThinkingBiomed for the treatment of solid tumors. It utilizes a proprietary "CAR-INK" platform, which is a specialized variant of Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapy. The therapy is designed to enhance the innate tumor-killing capabilities of NK cells through the expression of a chimeric antigen receptor, allowing for targeted recognition and destruction of solid tumor cells. As of early 2024, TB-005 is in the early research and development or preclinical validation phase, with specific molecular targets not yet publicly disclosed.
- Other names
- TB-005 CAR-INK cell therapyTB005 CAR-INK cell therapyTB 005 CAR-INK cell therapy
Beyond the preview
Go deeper on TB-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TB-005.